Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim By David Jagielski – Jun 7, 2024 at 9:00AM ...

--The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion ...

Recursion Pharmaceuticals , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia for $688 million in an all-stock deal ...

Recursion Pharmaceuticals just acquired a pair of AI-related biotechs. This could bolster its drug discovery capabilities and better help its clients. But the stock is high-risk and requires a ...

Recursion's AI-Powered Drug Revolution Recursion is a clinical-stage TechBio company that is fundamentally built upon the principles of artificial intelligence and machine learning.

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create ...

The Utah-based pharmaceutical company has trained a large language model to enable scientists to tap into dozens of machine learning models at once, saving them time during drug development.

The latest sign of investors’ unrelenting demand for all things artificial intelligence related: a record rally in drug discovery firm Recursion Pharmaceuticals Inc. following an investment from ...